Cardiac PPARalpha expression in patients with dilated cardiomyopathy

Eur J Heart Fail. 2006 May;8(3):290-4. doi: 10.1016/j.ejheart.2005.09.003. Epub 2005 Nov 22.

Abstract

Background: The peroxisome proliferator-activated receptor alpha (PPARalpha) is a central regulator of myocardial fatty acid (FA) metabolism implicated in the pathogenesis of heart failure.

Aims: To characterize PPARalpha regulation in human dilated cardiomyopathy (DCM), we studied the expression of cardiac PPARalpha, cardiac carnitine palmitoyl-transferase I (CPT-1), a major PPARalpha target gene, and of the cardiac glucose transporter GLUT-4 in patients with DCM.

Methods: Left ventricular biopsies were taken from patients with DCM (n=16) and control subjects (n=15), and mRNA expression was quantitated using real-time PCR (SYBR((R))Green) and protein expression was measured by Western immunoblotting.

Results: Left ventricular PPARalpha mRNA levels were significantly increased in the DCM group compared to the control group (136+/-25.4% vs. control, p<0.01). Consistently, DCM patients had a significantly higher cardiac CPT-1 mRNA expression (147+/-51% vs. control, p<0.05) compared to the control group. Cardiac GLUT-4 expression was similar in both groups.

Conclusion: Elevated cardiac PPARalpha levels followed by an induction of cardiac CPT-1 expression may result in increased fatty acid metabolism for cardiac energy production in DCM, suggesting a specific cardiac metabolic program in human DCM compared to other types of cardiomyopathy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Cardiomyopathy, Dilated / metabolism*
  • Carnitine O-Palmitoyltransferase / genetics
  • Female
  • Glucose Transporter Type 4 / genetics
  • Humans
  • Male
  • Middle Aged
  • Myocardium / metabolism*
  • PPAR alpha / genetics*
  • RNA, Messenger / analysis

Substances

  • Glucose Transporter Type 4
  • PPAR alpha
  • RNA, Messenger
  • Carnitine O-Palmitoyltransferase